We are live on ! Find out more

2,883 hedge funds and large institutions have $106B invested in Pfizer in 2024 Q1 according to their latest regulatory filings, with 193 funds opening new positions, 1,228 increasing their positions, 1,247 reducing their positions, and 216 closing their positions.

New
Increased
Maintained
Reduced
Closed

2% less repeat investments, than reductions

Existing positions increased: 1,228 | Existing positions reduced: 1,247

1.64% less ownership

Funds ownership: 68.99%67.35% (-1.6%)

2% less funds holding

Funds holding: 2,9412,883 (-58)

6% less capital invested

Capital invested by funds: $112B → $106B (-$6.65B)

11% less first-time investments, than exits

New positions opened: 193 | Existing positions closed: 216

23% less funds holding in top 10

Funds holding in top 10: 4031 (-9)

42% less call options, than puts

Call options by funds: $2.2B | Put options by funds: $3.82B

Holders
2,883
Holders Change
-58
Holders Change %
-1.97%
% of All Funds
41.43%
Holding in Top 10
31
Holding in Top 10 Change
-9
Holding in Top 10 Change %
-22.5%
% of All Funds
0.45%
New
193
Increased
1,228
Reduced
1,247
Closed
216
Calls
$2.2B
Puts
$3.82B
Net Calls
-$1.62B
Net Calls Change
-$615M

PFE Hedge Fund Activity: Q1 2024 in Review

2,883 of the 6,959 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q1 2024, worth a combined $106B — down 5.9% from $112B a quarter earlier.

Sellers outnumbered buyers: 216 funds closed out of PFE and 193 opened new positions — a net loss of 23 holders — while 1,247 trimmed existing stakes and 1,228 added.

The largest buyer was Charles Schwab, adding an estimated $499M. The largest seller was Wellington Management Group, cutting an estimated $1.71B.

  • 2,883 institutional investors held Pfizer (PFE) as of Q1 2024, down from 2,941 in Q4 2023.
  • Funds reported $106B of Pfizer stock for Q1 2024, down 5.9% quarter-over-quarter.
  • 193 funds opened new Pfizer positions in Q1 2024 and 216 closed out, a net change of -23 holders.
  • The largest Pfizer buyer in Q1 2024 was Charles Schwab, an estimated $499M added.
  • The largest Pfizer seller in Q1 2024 was Wellington Management Group, an estimated $1.71B sold.

Based on aggregated 13F filings for Q1 2024.